1/22/2008

The FDA has granted Novartis AG approval to market a combination of its blood-pressure lowering drug Tekturna and the diuretic HCT in a single-tablet formulation, the company announced Monday. The combination drug proved more effective in lowering blood pressure than either component alone in clinical trials.

Related Summaries